Treatment
Treatment 09/03/2012
Rates of MI, stroke, non-AIDS cancer climb with longer ART duration
Yearly rates of death from myocardial infarction, non-AIDS cancer, and stroke rise.
Treatment 09/03/2012
Sangamo presents new clinical data at CROI 2012 demonstrating persistent positive effects of ZFN Therapeutic® for "functional cure" of HIV/AIDS
Data highlight positive effects of SB-728-T on immune system and viral load reduction and further validate strategy of ongoing Phase 2 trials.
Treatment 09/03/2012
New treatment presented for chronic diarrhea in HIV/AIDS patients
Crofelemer is an intraluminal, locally active, first in class antidiarrheal agent that has demonstrated therapeutic benefit in clinical studies.
Treatment 09/03/2012
Drug helps purge hidden HIV virus, study shows
This study is the first to demonstrate that the biological mechanism that keeps the HIV virus hidden and unreachable by current antiviral therapies can be targeted and interrupted in humans, providing new hope for a strategy to eradicate HIV completely.
Treatment 09/03/2012
Diabetes drug halts atherosclerosis progression in HIV-infected patients
Metformin treatment seen to prevent growth of calcium deposits in coronary arteries.
Treatment 09/03/2012
Time HIV Tx starts has no impact on IQ
Neurological development of children infected with HIV does not appear to be influenced by the decision on when to start antiretroviral therapy.
Treatment 09/03/2012
CHARTER study: Asymptomatic cognitive problems "harbinger" for future neurologic decline
Individuals with asymptomatic neurocognitive impairment tend to progress to symptomatic HIV-associated neurocognitive disorders more frequently than those with normal cognitive functioning.
Treatment 09/03/2012
ViiV’s dolutegravir continues to show well after 96 weeks, versus Sustiva, for first-time treatment
Dolutegravir is a second-generation integrase inhibitor that is active against HIV strains resistant to first-generation inhibitors Isentress (raltegravir) and elvitegravir.
Treatment 09/03/2012
Data show Gilead’s Quad regimen for HIV non-inferior to protease-based regimen at 48 weeks in second pivotal Phase 3 study
Quad is non-inferior to a protease-based regimen of ritonavir-boosted atazanavir plus Truvada® at 48 weeks of therapy among HIV-1 infected treatment-naïve adults.
Treatment 09/03/2012
Tenofovir pro-drug GS-7340 shows good safety and efficacy in short study
GS-7340, a pro-drug of tenofovir that reaches higher concentrations in cells, has superior efficacy and may be more suitable for inclusion in co-formulations.
Treatment 09/03/2012
PEPFAR funding linked to lower death rate from all causes in Africa
PEPFAR funding for HIV programmes lowered the risk of death in countries receiving funds by around 16% between 2004-2008, without any clear indication that funding for HIV was having a negative effect on the ability to fight other diseases.
Treatment 07/03/2012
Gilead ’s Quad single tablet regimen for HIV non-inferior to Atripla® in pivotal Phase 3 study
Quad currently under review for marketing approval by U.S. and European regulatory agencies.
Treatment 07/03/2012
NIH-funded study defines treatment window for HIV+ children infected at birth
The first year of life may present a critical treatment window for minimizing impairments in brain development due to HIV.
Treatment 07/03/2012
CD8 activation and naive CD4s predict CD4 gains through 10 to 15 years of ART
Lower levels of activated CD8 T cells 3 to 5 years after starting antiretroviral therapy predicted significantly greater CD4 gains in years 10 to 15 of treatment among people with consistently well-controlled viremia.
Treatment 07/03/2012
Studies disagree on danger in detectable viral load under 50 copies
Three studies disagree on whether a detectable viral load under 50 copies poses a risk of confirmed virologic rebound.
Treatment 07/03/2012
Slower virologic response in pregnant women starting ART in France
Pregnant women are 40% to 50% less likely to reach a viral load below 50 copies 3 and 6 months after starting antiretroviral therapy.
Treatment 07/03/2012
Review questions efficacy of two WHO first-line TDF regimens
Antiretroviral regimens are more than the sum of their parts.
Treatment 07/03/2012
New IAPAC recommendations on getting and keeping people in care for HIV
Successful retention in care and ARV adherence have been shown to reduce the transmission of HIV. They also help solve the issues of viral resistance and treatment failure—in addition to improving the lives of HIV-positive people.
Treatment 07/03/2012
Diet improves lipids in HAART-treated patients
A dietary intervention introduced before HIV-infected patients begin HAART prevents dyslipidemia that is typically associated with treatment.
Treatment 03/03/2012
FDA: Important info about interactions between certain HIV drugs and cholesterol-lowering statin drugs
Protease inhibitors and statins taken together may raise the blood levels of statins and increase the risk for muscle injury (myopathy).
More...
